Esophageal squamous cell carcinoma
Conditions
Interventions
Experimental group:radiotherapy + tislelizumab
Sponsors
Department of Thoracic Oncology, the Second Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Eastern Cooperative Oncology Group (ECOG) score =80 points; 2. Aged 18-75 years; 3. Esophageal squamous cell carcinoma was confirmed by histopathology; 4. American Joint Committee (AJCC) Edition 8 TNM patients with locally advanced (II-IVA) stage inoperable (including patients refusing surgery); 5. No serious hematopoietic function, abnormal heart, lung, liver, kidney function and immune deficiency, normal organ and bone marrow function; 6. No matter the status of PD-1/PD-L1; 7. Expected survival > 3 months; 8. There is no primary tumor in other sites before treatment or there is primary tumor in other sites but it has been controlled for more than 5 years; 9. Less than 2 cycles of previous chemotherapy; 10. Have not received radiotherapy, targeted therapy or immunotherapy.
Exclusion criteria
Exclusion criteria: 1. Patients with poor general condition who cannot tolerate chemotherapy; 2. The esophagus is completely obstructed and cannot take fluids; 3. Patients with a history of esophageal cancer surgery or high risk of fistula, perforation and bleeding due to primary tumor invasion; 4. Participate in other clinical trials; 5. Have interstitial pneumonia or previous history of interstitial pneumonia; 6. Have received radiation therapy in the planned radiotherapy area; 7. Distant metastasis has occurred.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Recurrence free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactHu Wei
The Second Affiliated Hospital of Zunyi Medical University
Outcome results
None listed